Ginkgo Q3 2023: Total revenue $55M (-17% YoY); Cell Engineering up 51%; revises FY23 outlook

Ginkgo Bioworks Holdings, Inc.

2023-Q3 EPS reported -$0.35 revenue$216,700,000

Cell Engineering revenue $37M (+51% YoY); Biosecurity revenue $18M with 62% gross margin.
Loss from ops $(286)M including $96M impairment charge; Adj. EBITDA $(84)M vs $(72)M prior year.
Added 21 new Cell Programs in Q3, 40% growth YoY; full-year target revised to 80-85 programs.
New partnerships: Pfizer RNA drug discovery (up to $331M milestones) and Google Cloud AI deal.
FY23 revenue guidance cut to $250-260M; Cell Engineering $145-150M; Biosecurity up to $110M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $55 million, net income $(286) million. Guidance lowered.

Period: third quarter ended September 30, 2023
Revenue: $55 million
Net income: $(286) million
Guidance: lowered
Result: reported results

Exact text from the filing

of next-generation biological intelligence capabilities, including AI-based epidemic forecasting Third Quarter 2023 Financial Highlights • Third quarter 2023 Total revenue of $55 million, down from $66 million in the comparable prior year period, a decrease of 17% primarily driven by the expected ramp down of K-12 testing in Ginkgo’s Biosecurity segment • Third

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.